Immunocompromised
Showing 26 - 50 of 804
Immunocompromised, Hematologic Malignancy, Post Hematopoietic Stem Cell Transplant Trial in Toronto (High Flow Nasal Cannula or
Active, not recruiting
- Immunocompromised
- +4 more
- High Flow Nasal Cannula or Low Flow Nasal Cannula
-
Toronto, Ontario, CanadaMount Sinai Hospital
Apr 4, 2022
Human Papilloma Virus Infection Trial (9-valent HPV vaccine)
Not yet recruiting
- Human Papilloma Virus Infection
- 9-valent HPV vaccine
- (no location specified)
Jul 11, 2022
COVID-19, SARS-CoV-2 Trial in Worldwide (AZD1222)
Active, not recruiting
- COVID-19, SARS-CoV-2
- AZD1222
-
Ajmer, India
- +12 more
Nov 10, 2022
BK Polyomavirus Trial in Philadelphia (BK-virus specific CTLs)
Recruiting
- BK Polyomavirus
- BK-virus specific CTLs
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Mar 15, 2022
Herpes Zoster Subunit Vaccine During Pregnancy in Adult
Not yet recruiting
- Herpes Zoster
- Data collection
- (no location specified)
Mar 31, 2023
Immunocompromised Haematology Patients
Active, not recruiting
- Covid19
- +2 more
- Blood test
-
Stoke-on-Trent, United KingdomUniversity Hospitals of North Midlands NHS Trust
Feb 17, 2022
Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host Trial in Cincinnati (Viral Specific VST Infusion)
Recruiting
- Viral Infection
- +2 more
- Viral Specific VST Infusion
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Apr 7, 2022
Anti COVID-19 Vaccine in Immunocompromised Patients:Cohort Study
Completed
- Covid19
- COVID-19 Vaccines
- Serologic immune response evaluation
-
Santiago, ChileRed de Salud UC Christus
Nov 15, 2021
Diarrhea Caused by Drug, Dysbiosis Trial in Syracuse (Florajen Digestion Supplementation, Placebo Supplementation)
Withdrawn
- Diarrhea Caused by Drug
- Dysbiosis
- Florajen Digestion Supplementation
- Placebo Supplementation
-
Syracuse, New YorkSUNY Upstate Medical University
Oct 19, 2021
Influenza Viruses Isolated From Immunocompromised Children and
Recruiting
- Influenza, Human
- Blood sample
- +4 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Dec 5, 2021
Severely Immunocompromised HIV Patients Trial in Salvador, Rio de Janeiro, Porto Alegre (Dolutegravir 50 mg, Efavirenz-based
Completed
- Severely Immunocompromised HIV Patients
- Dolutegravir 50 mg
- Efavirenz-based regimens
-
Salvador, Bahia, Brazil
- +2 more
Mar 15, 2022
A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies
Recruiting
- Immunocompromised Patients
- Data collection
-
Paris, Ile De France, FranceAssistance Publique - Hôpitaux de Paris (AP-HP) - Cochin Hospita
Jul 5, 2022
Meningococcal Vaccine Trial in Czechia, Poland, Turkey (Trumenba)
Recruiting
- Meningococcal Vaccine
- Trumenba
-
Brno 2, Czechia
- +9 more
Jun 20, 2022
Invasive Group B Streptococcus Disease Burden and Its
Recruiting
- Invasive Infection
- +3 more
- No Intervention in This study
-
Serdang, Selangor, MalaysiaFaculty of Medicine and Health Sciences
Feb 11, 2023
Patterns of Immune Response to COVID 19 Vaccination
Recruiting
- Immune Response to Covid 19 Vaccination
- Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)
-
Cairo, Dokki, EgyptNational Research Center
Jun 5, 2022
Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck Trial in Tucson, Tampa
Terminated
- Cutaneous Squamous Cell Carcinoma
- Cutaneous Squamous Cell Carcinoma of the Head and Neck
-
Tucson, Arizona
- +1 more
Nov 2, 2022
Pneumonia in ImmunoCompromised - Use of Karius Test for
Recruiting
- Pneumonia, Bacterial
- +4 more
- Karius Test
-
Duarte, California
- +9 more
Jul 29, 2021
the Incidence of PICC-related Complications Trial (PICC)
Not yet recruiting
- the Incidence of PICC-related Complications
- PICC
- (no location specified)
Nov 17, 2022
Chronic Pulmonary Aspergillosis Trial in Poitiers (inhaled Ambisome®, inhaled , Itraconazole)
Recruiting
- Chronic Pulmonary Aspergillosis
- inhaled Ambisome®
- +2 more
-
Poitiers, FranceCHU Poitiers
Feb 9, 2022
COVID-19 Vaccination and Breakthrough Infections Among Persons
Completed
- Immunocompromised
- +5 more
- BNT162b2 (Tozinameran)
-
New York, New YorkPfizer Inc.
Jul 1, 2022